NADOLOL Drug Interactions
Also known as: Nadolol
Nadolol (Nadolol) is a type of medicine called a beta-blocker. It is prescribed to help manage chest pain (angina pectoris) and to lower high blood pressure (hypertension). By blocking certain natural chemicals in the body, Nadolol helps to slow the heart rate and relax blood vessels, making it easier for the heart to pump blood.NADOLOL has 7 documented drug interactions in our database, including 0 contraindicated, 0 major, 0 moderate, and 7 minor interactions.
0
Contraindicated
0
Major
0
Moderate
7
Minor
The interaction between nadolol and sertraline is considered minor. While both drugs can independently cause bradycardia, sertraline has minimal CYP2D6 inhibition, and nadolol is primarily renally cleared, reducing the likelihood of a significant pharmacokinetic interaction.
Mechanism
Nadolol is primarily cleared renally, and its metabolism is not significantly affected by CYP2D6 inhibition. Sertraline is a weak inhibitor of CYP2D6, therefore, it is unlikely to significantly alter nadolol plasma levels. Both drugs can have bradycardic effects, leading to a theoretical additive pharmacodynamic effect.
Clinical Management
Generally, no specific dose adjustments are required when co-administering nadolol and sertraline. However, clinicians should monitor patients for signs of excessive bradycardia or hypotension, especially during initiation or dose changes of either medication. If such symptoms occur, consider reducing the dose of one or both drugs.
The interaction between nadolol and fluoxetine is considered minor. While fluoxetine is a potent CYP2D6 inhibitor, nadolol is primarily eliminated renally with minimal CYP2D6 metabolism, making a significant pharmacokinetic interaction unlikely.
Mechanism
Fluoxetine is a potent inhibitor of CYP2D6. However, nadolol is predominantly cleared by the kidneys and is not significantly metabolized by CYP2D6, thus its plasma levels are not expected to be significantly altered by fluoxetine.
Clinical Management
No specific dose adjustments for nadolol are typically required when co-administered with fluoxetine. Monitor patients for additive pharmacodynamic effects such as excessive bradycardia or hypotension, especially if they have pre-existing cardiac conditions or are on other medications that lower heart rate or blood pressure.
A clinically significant pharmacokinetic interaction between nadolol and citalopram is unlikely due to nadolol's primary renal clearance and citalopram's minimal inhibition of relevant CYP enzymes. However, both drugs can independently affect heart rate, and an additive pharmacodynamic effect resulting in bradycardia is theoretically possible, though rarely clinically significant.
Mechanism
Nadolol is primarily eliminated renally, with minimal involvement of CYP450 enzymes. Citalopram is a weak inhibitor of CYP2D6 and other CYP enzymes, which are not primary metabolic pathways for nadolol. Therefore, a pharmacokinetic interaction is not expected. A minor pharmacodynamic interaction is possible due to the additive potential for bradycardia.
Clinical Management
Generally, no specific dose adjustments or enhanced monitoring are required for this combination. Monitor patients for signs of excessive bradycardia or hypotension, especially if they have pre-existing cardiac conditions or are on other bradycardia-inducing medications. If severe bradycardia occurs, consider dose reduction of one or both agents.
The interaction between nadolol and fluoxetine is considered minor. While fluoxetine is a potent CYP2D6 inhibitor, nadolol is primarily renally cleared with minimal CYP2D6 involvement, reducing the risk of pharmacokinetic interaction. However, both drugs can independently cause bradycardia, so additive pharmacodynamic effects are theoretically possible.
Mechanism
Fluoxetine is a potent inhibitor of CYP2D6. However, nadolol is primarily eliminated via renal excretion, with minimal metabolism by CYP2D6, thus its plasma levels are not significantly affected by CYP2D6 inhibition. Both drugs can cause bradycardia, leading to a potential additive pharmacodynamic effect.
Clinical Management
Generally, no specific dose adjustments are required for nadolol when co-administered with fluoxetine due to nadolol's renal clearance. However, clinicians should monitor patients for signs of excessive bradycardia or hypotension, especially when initiating or significantly changing doses of either medication. If symptomatic bradycardia occurs, consider dose reduction or alternative agents.
The interaction between nadolol and escitalopram is generally considered minor. While both drugs can independently cause bradycardia, escitalopram has minimal impact on nadolol's metabolism, and nadolol is primarily renally cleared.
Mechanism
Escitalopram is a weak inhibitor of CYP2D6, but nadolol is primarily eliminated renally with minimal CYP2D6 involvement, thus pharmacokinetic interaction is unlikely. A theoretical additive pharmacodynamic effect leading to bradycardia is possible, though not frequently observed.
Clinical Management
No specific dose adjustments are typically required for this combination. Monitor patients for signs of excessive bradycardia or hypotension, especially if they are sensitive to beta-blockers or have pre-existing cardiac conditions. If symptoms occur, consider adjusting the dose of either medication.
The interaction between nadolol and paroxetine is considered minor. Nadolol is primarily renally cleared, and its metabolism is minimally affected by CYP2D6 inhibition, which is the primary mechanism by which paroxetine interacts with other beta-blockers. While both drugs can independently cause bradycardia, an additive effect is unlikely to be clinically significant with nadolol.
Mechanism
Nadolol is predominantly eliminated by renal excretion with minimal hepatic metabolism, thus it is not significantly affected by paroxetine's potent CYP2D6 inhibitory activity. Although both drugs can independently cause bradycardia, a significant pharmacodynamic interaction leading to enhanced bradycardia is not expected given nadolol's clearance pathway.
Clinical Management
No specific dose adjustments are typically required for nadolol when co-administered with paroxetine. Standard monitoring for the individual effects of each drug, such as heart rate and blood pressure, is recommended. If bradycardia or hypotension occurs, consider other contributing factors or individual patient sensitivities rather than this specific interaction.
Nadolol is primarily renally cleared, and its metabolism is not significantly impacted by CYP450 enzymes. Therefore, fluvoxamine, a potent CYP1A2 and CYP2C19 inhibitor, is unlikely to cause a significant pharmacokinetic interaction with nadolol.
Mechanism
Nadolol is predominantly eliminated via renal excretion as unchanged drug, with minimal hepatic metabolism. Fluvoxamine's inhibitory effects on CYP1A2 and CYP2C19 enzymes would not significantly alter nadolol's pharmacokinetics.
Clinical Management
No specific dose adjustments or enhanced monitoring are generally required for this combination due to the minimal pharmacokinetic interaction. However, clinicians should always monitor patients for expected therapeutic effects and adverse reactions of both medications, especially if other interacting drugs are present or renal function is impaired.
For complete prescribing information:
View full NADOLOL monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.